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The diffusion capacity for nitric oxide (DLNO) is independent of pulmonary capillary blood
volume and equals the membrane diffusing capacity. Therefore the DLNO could be more sensi-
tive in detecting alveolar destruction than the DLCO.
We measured flow-volumes curves, DLNO, DLCO, the transfer coefficients KNO (DLNO/VA)
and KCO (DLCO/VA) and performed computed tomography (CT) scans in 263 randomly selected
heavy smokers. Subjects with areas 1% of the total lung volume showing an attenuation
<950 Hounsfield Units were considered to have emphysema.
In 36 subjects emphysema was diagnosed with CT, a low KNO was present in 94 subjects, and
in 95 subjects a FEV1/FVC ratio <70% was seen. The area under the ROC curve for detection
CT-based emphysema was 0.894 for the KNO, 0.822 for the KCO and 0.795 for FEV1/FVC,
meaning that the KNO has a slightly higher sensitivity to detect emphysema than the KCO
and FEV1/FVC. The positive predictive value of KNO however was low (34.7%), while the nega-
tive predictive value of KNO was very high (98.2%), indicating an emphysema exclusion test.
The DLNO/DLCO ratio is significantly higher in the study group compared to normal subjects.
ª 2009 Elsevier Ltd. All rights reserved.Lee, Spaarne Ziekenhuis,
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The pathological findings in chronic obstructive pulmonary
disease (COPD) are chronic bronchitis, small airways
disease and emphysema.1 Chronic bronchitis is clinically
characterized by cough and increased sputum production;
airway obstruction can be measured by spirometry..
Early diagnosis of emphysema in smokers 1893However, a diagnosis of emphysema, especially early in the
disease, is often more difficult to make.
Emphysema can be quantified by measuring the
percentage of low attenuation areas on high resolution
computed tomography (HRCT) scans, which has good
correlation with the amount of emphysema present in lung
specimens.2 The HRCT emphysema indices are stronger
correlated with the carbon monoxide (CO) diffusion
capacity (DLCO) and coefficient (KCO) than with the FEV1
and FEV1/FVC ratio.
3e5
Nitric oxide (NO) has a much stronger affinity for hae-
moglobin than CO, therefore the NO diffusion capacity
(DLNO) is not limited by the pulmonary capillary blood
volume (Vcap) and equals the true membrane diffusing
capacity (Dm).6e8 Because emphysema is characterized by
loss of functional alveoli,9 and thus a decrease in Dm, we
hypothesized that the DLNO is more sensitive in diagnosing
emphysema than the DLCO. We are aware of one other
study measuring the DLNO in subjects with COPD,10 in
which a very short breathholding time of 3 s was used,
which makes the results difficult to compare with studies in
which a breathholding time of 10 s was used.
A simultaneous single breath DLNO and DLCO measure-
ment gives additional information about the cause of the
diffusion deficit.11,12 In case of decreased Vcap, the DLCO
will lower but the DLNO not, therefore the DLNO/DLCO ratio
will increase. With a decreased alveolocapillary membrane
surface, both the DLNO and DLCO will be hampered, and the
DLNO/DLCO ratiowill beunchanged.A lowering of the ratio is
also possible, as the DLNO is influenced by alveolocapillary
membrane surface only. For example, subjects with pulmo-
nary hypertension have a higher DLNO/DLCO ratio than
normal subjects.12,13 TheDLNO/DLCO ratio is independent of
exercise intensity,14 although others found a slight decrease
from rest to exercise using a rebreathing technique.15 Recent
research in healthy subjects showed an inverse relationship
between the DLNO/DLCO ratio and the thickness of alveolar
membrane and capillary sheet.16
The main question of this study was whether the DLNO is
more sensitive in diagnosing emphysema in a large group of
heavy smokers than the DLCO. The secondary question was
whether the DLNO/DLCO ratio differs in subjects with
emphysema compared to healthy individuals.
Methods
Subjects
All subjects were participating in the NELSON-project,
a Dutch-Belgian multi-centre lung cancer screening trial.17
The subjects were all male, 50e75 years of age with
a smoking history of at least 20 pack years. The NELSON-
project was approved by the Dutch ministry of health and
by the local ethics committee; informed consent was
obtained from all participants. A random selection of the
screened subjects performed pulmonary function testing.
Pulmonary function testing
Spirometry and flow-volume curves were obtained via
pneumotachography, according to ERS guidelines.18 Noreversibility testing was done. A FEV1/FVC ratio <70% was
labelled as abnormal, according to the GOLD classification.19
The DLNO and DLCO were measured in one single breath
maneuver, with test gas containing a mixture of CO 0.25%,
He 9.17%, and NO 8 ppm with balance air. A small amount NO
from a separate tank containing 750 ppm NO in nitrogen
(Hoekloos Medical; Schiedam, the Netherlands) was added
to the test gas directly before each measurement to dilute
to 8 ppm. The procedure was performed with an effective
breathholding period of 10 s (Jones and Meade method20),
discard volume of 750 mL, and a sample volume 750 mL.
Standard DLCO measurement was performed on a MasterLab
Pro (Erich Jaeger GmbH, Germany). NO-concentration was
measured in inspiratory and expiratory gas mixture with the
aid of a chemoluminescence analyzer (CLD 77 AM; Eco
Physics; Zurich, Switzerland (lower detection limit 0.02e
0.05 parts per billion (ppb); upper detection limit 10 ppm;
reaction time 0.1 s)). The chemoluminescence analyzer was
calibrated with 5 ppm NO in nitrogen and NO-free air on
a weekly basis. All connections between the NO analyzer and
the inspiratory and expiratory bags were made of poly-
tetrafluoroethylene (Teflon; DuPont; Wilmington, DE) or
stainless steel, which do not interact with NO. The alveolar
volume (VA) and DLCO were calculated according to Euro-
pean Respiratory Society recommendations,21 the DLNO was
calculated according to the method described by Borland
et al.6 Endogenous NO levels and CO backpressure were
ignored, and smoking was allowed until 24 hours before
testing. A correction for haemoglobin (Hb) levels was not
made, because Stam et al.22 showed that in healthy volun-
teers Hb correction only has a very limited effect.
The DLCO and DLNO were corrected to BTPS conditions,
and a minimum of two measurements was performed, in
which a variability of 10% or less for the VA and DLCO was
acceptable. All pulmonary function values are given as
a mean with standard deviation (SD), and as percentage of
predicted values (%pred)18,21,23. For the DLNO we used
references equations that we published previously.24 Values
below1.64*SDwere considered abnormal. TheDLNO/DLCO
and FEV1/FVC ratios are expressed as absolute values.CT Scanning and emphysema quantification
The CT scan was performed on a 16 detector-row scanner
(Mx8000 IDT or Brilliance 16P, Philips Medical Systems,
Cleveland, OH), scan time was 12 s from apex to base, in
spiral mode with 16 0.75mm collimation, 1.0 mm recon-
struction thickness, without contrast-injection.
After automatic lung segmentation connecting all areas
below 500 Hounsfield Units (HU) starting in the trachea
and excluding the main bronchi, quantification of emphy-
sema was done with a density mask method,25 with
a threshold of 950 HU. Emphysema scores (ES) were
calculated as the volume with an attenuation <950 HU
indexed to total lung volume. Subjects with an ES 1%
were considered to suffer from emphysema.3,26,27
Statistics
Values are given as means with standard deviations (SD) and
as percentage of predicted values. Spearman correlation
Table 2 Correlation coefficients of the emphysema score
versus pulmonary function data (*p< 0.01).
Emphysema score
FEV1/FVC 0.43*
DLCO, %predicted 0.26*
KCO, %predicted 0.38*
DLNO, %predicted 0.29*
KNO, %predicted 0.50*
1894 I. van der Lee et al.coefficients were used to assess significant relationships;
the area under the curve (AUC) of the receiver operator
curves (ROC) were used to assess the capability of the
pulmonary function parameters to signal the absence or the
presence of emphysema. One-way ANOVA was used to
compare differences between groups. All statistics were
calculated with SPSS for Windows release 17 (SPSS Inc,
Chicago, USA).
Results
A total of 263 male subjects were included in the study.
Characteristics of the study population are displayed in
Table 1. Emphysema (ES 1) was present in 36 subjects
(13.6%). According to spirometric criteria, 168 subjects had
normal spirometry or were in GOLD 0, 68 subjects were in
GOLD 1, 26 subjects were in GOLD 2, and 1 subject was in
GOLD class 3.19 Significant negative correlations were
observed between all diffusion capacity parameters, the
FEV1/FVC ratio and the ES (Table 2). The mean DLNO/DLCO
in the entire sample ratio was 4.9, which is significantly
higher (p< 0.001) than the value of 4.4 we measured
earlier in healthy subjects,24 and higher than the value of
4.3 measured by Borland.6
The AUC of the ROC curves (Fig. 1) showed highest
values for KNO (%pred) to detect emphysema; KCO (%pred)
and FEV1/FVC had slightly lower values (Table 3).
The sensitivities and specificities of all parameters to
detect emphysema are given in Table 4, as well as the
positive (PPV) and negative (NPV) predictive values. The
NPV of KNO is very high indicating that a normal KNO
virtually excludes emphysema. The low PPV values indicate
that an abnormal KCO, KNO or FEV1/FVC are often present
in the absence of emphysema. This is graphically shown in
Fig. 2. Subjects with low KNO values, subjects with
emphysema on CT and subjects with a FEV1/FVC <70% form
partially overlapping groups, which can be illustrated with
a non-proportional Venn diagram (Fig. 3). The mean DLNO/
DLCO ratio was 5.0 (SD 0.49) in all subjects with abnormal
test results (i.e. low KNO, FEV1/FVC <70% or ES> 1%, thus
all subjects included in the Venn diagram), versus 4.8 (SD
0.37) in subjects with normal test results, which is
a statistical significant difference (p< 0.001).Table 1 Characteristics of the study population, nZ 263.
Mean Range SD
Age, years 60.3 52.3e76.9 5.4
Height, m 1.78 1.61e2.00 0.07
VC, %pred 105.5 61.1e147.5 13.2
FEV1/FVC, %pred 93.6 42.3e113.9 11.7
FEV1, %pred 97.7 43.0e140.8 16.8
FEV1/FVC 71.5 32.4e86.9 9.0
DLCO, %pred 87.4 49.8e140.4 16.1
KCO, %pred 84.4 46.6e140.2 15.9
DLNO, %pred 87.5 45.3e121.3 13.5
KNO, %pred 90.4 53.7e121.6 12.4
DLNO/DLCO ratio 4.9 3.8e6.4 0.4
ES (emphysema score) 0.6 0.0e14.7 1.5Discussion
The main finding of this study is the fact that the KNO has
(slightly) greater power for the detection of CT-based
emphysema than the KCO. Another important finding of this
study is the fact that the DLNO/DLCO ratio in this group of
heavy (ex) smokers is significantly higher than in healthy
subjects. The values we use for the DLNO/DLCO ratio in
healthy subjects is similar to those found by other
researchers: Aguilaniu et al. found a DLNO/DLCO ratio of
4.7528 and Zavorsky et al. published a ratio of 4.52 in his
earlier study.14 The DLNO/DLCO ratio in the study group
reaches values found in subjects with pulmonary arterial
hypertension.11e13 The DLNO/DLCO ratio is even more
increased in the group of subjects with abnormal results for
FEV1/FVC, KNO or emphysema score. Unfortunately, the
study group is too small to measure a dose response rela-
tionship between pack years smoking and the DLNO/DLCO
ratio or other pulmonary function tests. Because of the
variable individual susceptibility for the toxic effects of
cigarette smoke, very large cohorts are needed to find
a significant relationship between pack years smoking andFigure 1 ROC curves of pulmonary function parameters as
a diagnostic for CT-based emphysema.
Table 3 Area under the curve (AUC) with 95% confidence
intervals (95% CI) of the receiver operator curves (ROC) for
detecting of emphysema (ES 1).
AUC p 95%CI
FEV1, %pred 0.656 <0.003 0.551e0.761
FEV1/FVC, %pred 0.795 <0.001 0.710e0.880
DLCO, %pred 0.727 <0.001 0.622e0.833
KCO, %pred 0.822 <0.001 0.757e0.887
DLNO, %pred 0.711 <0.001 0.608e0.815
KNO, %pred 0.894 < 0.001 0.850e0.938
Figure 2 Scatterplot of pulmonary function parameters
versus CT-based emphysema.
Early diagnosis of emphysema in smokers 1895pulmonary function tests. The increased DLNO/DLCO ratio
is observed in the complete study sample, where most
subjects had no CT-detectable emphysema.
The Roughton and Forster equation29 assumes that
DmCO and Vcap are independent components by stating
that the total DLCO resistance is a sum of two resistances.
However, capillary blood flow is a prerequisite for a DmCO
to exist and so DmCO must be dependent on capillary blood
flow. Furthermore, research has pointed out that the DmCO
is dependent on haemoglobin concentration, and indeed
a relationship between DmCO and Vcap exists.30 If the
DmCO and the Vcap components are dependent variables,
the separation of DLCO in these two components is a pure
mathematical concept, and simplifies the involved patho-
physiology. Another important argument against the use of
DmCO and Vcap is the fact that the correct calculation is
still open for debate: disagreement exists on the correct Q-
value needed for the Roughton and Forster equation. Using
DLNO to obtain an estimate for DmCO is also under debate:
some researchers use aZ 1.9710 and others use aZ 2.427 in
the DmCOZ DLNO/a equation. Therefore, in calculating
DmCO and Vcap one uses parameters that are based on an
assumption of independency, that have non-assessed clin-
ical value31 and the involved physiological principles have
been simplified. Furthermore, an ongoing but still unre-
solved debate which way DmCO should be calculated7,32,33
is present. By using the DLNO/DLCO ratio, we can avoid
these unresolved methodological problems; we expect that
the clinical utility of the DLNO/DLCO ratio will be greater
than the use of the components DmCO and Vcap. As DLNO is
not governed by capillary blood volume and DLCO is,
a strong relationship between DLNO/DLCO and Dm/Vcap is
logical, because the same factors influence both ratios.28
These are the main reasons that we choose NOT to use
calculated DmCO and Vcap values, but only DLNO/DLCO
ratios instead.Table 4 Sensitivity, specificity, positive predictive values
(PPV) and negative predictive values (NPV) of the measured
parameters to detect emphysema.
Sensitivity Specificity PPV NPV
DLCO 58.3% 81.5% 33.3% 92.5%
DLNO 50.0% 81.9% 30.5% 91.2%
KCO 88.9% 57.3% 24.8% 97.0%
KNO 91.7% 72.7% 34.7% 98.2%
FEV1/FVC 77.8% 70.1% 29.5% 95.2%The population in this study is slightly older than the
population we used for reference equations,24 Zavorsky
et al.33 showed that age dependent effects for the DLNO as
well as the DLCO are present. Whether the DLNO/DLCO
ratio is age dependent is not clear. Although further
research on this item is necessary, we are convinced that
the small age difference cannot explain the difference in
the DLNO/DLCO ratio in healthy subjects and heavy
smokers.
The cause of alveolar destruction in emphysema is
subject of research, but until now it is not clear whether
apoptosis of alveolar epithelial cells or apoptosis of endo-
thelial cells are the origin of the pathological destruction.34
In experimental animal models, blockage of vascular
endothelial growth factor (VEGF) resulted in endothelial
cell apoptosis and subsequent development of emphy-
sema.35 It is conceivable that microvascular malfunctioning
is present in an early stage of the disease, later followed by
the development of tissue loss or measurable emphysema.
Another argument can be found in the development of
pulmonary hypertension secondary to COPD, which can be
seen in a subgroup of patients with severe COPD. The
classic explanation is that tissue hypoxia leads to vaso-
constriction, which in the end becomes irreversible due to
remodeling of the vascular wall. More recent insights points
at a completely different cause: microvascular changes are
the key factor in the development of secondary pulmonaryFigure 3 Non-proportional Venn diagram: the presence of
emphysema on CT (nZ 36), a decreased KNO (nZ 94) and
FEV1/FVC< 70% (nZ 95) are partially overlapping entities.
1896 I. van der Lee et al.hypertension, irrespective of pulmonary arterial oxygen
tension.36 This point at the possibility that vascular changes
are key factors in the cause and the consequence of the
progression of COPD.
The focus of pulmonologists on airway obstruction is
logical: it is the most distinguishing feature of COPD, and
strongly correlated with performance, quality of life and
survival. On the other hand, smoking induces a lot of
systemic effects, e.g. arteriosclerosis and delayed wound
healing due to endothelial dysfunction. These effects are
based on haematological spreading of toxic components of
cigarette smoke, why should the lungs be spared of these
effects? The focus of pulmonologists has always been more
on local ‘‘air borne’’ effects of smoking, instead of
‘‘systemic’’ effects.
It is remarkable to see (Fig. 3) that of the 133 subjectswith
one or more abnormal test results (e.g. low KNO, low FEV1/
FVC, etc), only 95 are diagnosed as COPD according to the
GOLD approach: using only spirometry 38 diseased subjects
are missed. There are 30 subjects with decreased KNO but
normal spirometry andno emphysemaonCT. This could point
at interstitial lungdisease, however after carefully reviewing
the scans this proved not to be the case. Obviously, other
processes than emphysema are responsible for this
phenomenon; microvascular changes are a good candidate
for the explanation of this phenomenon. Due to the design of
this study this hypothesis cannot be tested, further research
will be necessary to resolve this item.
The study results indicate that the combination of
spirometry and diffusion capacity detects almost all cases of
HRCT-diagnosed emphysema. On the other hand, abnormal
results for spirometry and diffusion capacity are not specific
for the presence of emphysema. A strong correlation
between the emphysema score and the DLNO cannot be
found, as the non-emphysematous lung parts do not influ-
ence the CT-based emphysema score.37 Emphysematous
tissue ventilates poorly and is less accessible for test gas, and
therefore cannot contribute to the uptake of NO or CO.
Emphysema will betray itself by lowered diffusion capacity,
but any diffusing capacity measure is also influenced by the
status of the better ventilating lung zones. In other words,
the diffusing capacity represents the functional status of
non-emphysematous lung tissue.37 Emphysema could be
considered as the last stage of an ongoing disease process of
the lung parenchyma, influencing pulmonary microstruc-
tures first, which cannot be visualized by CT scanning. The
microscopical damage leads to functional impairment and
our results are pointing to hypothesis that microvascular
pathology is an important early phenomenon. Based on our
observations, early detection of emphysema should also be
performed with measurement of the diffusion capacity
instead of spirometry only. The GOLD criteria19 are based on
spirometry only. By widening the clinical spectrum of COPD
than just airway obstruction solely, the measurement of the
diffusing capacity leads to better insight in the pathophysi-
ology of COPD. An ongoing discussion in pulmonary literature
is present concerning the focus on spirometry only in GOLD
criteria. It seems that the reason for this choice is that
spirometry is widely available inmany countries, aswell with
general practioners as in hospitals; the measurement of the
diffusion capacity is limited to pulmonary function labs.Based on our results, the combination of spirometry and
the diffusion capacity detects almost all cases of CT-based
emphysema. No great difference has been observed
between CO and NO diffusion capacity. Using this approach,
CT scanning for the quantification of emphysema is not
necessary, except in clinical trials in which quantification of
emphysema is an end-point. Spirometry, gas transfer and
CT-based emphysema are complementary and partially
overlapping entities (Fig. 3).
In this population-based study in heavy (ex) smokers the
correlation between pulmonary function tests and CT-
based assessment of emphysema is weaker than reported
earlier.38 This is not unexpected, because our subjects
were not selected on the presence of COPD by pulmonary
function testing. In studies in which such work-up bias was
present, one might expect stronger correlations, due to the
presence of more severe disease. As a consequence, the
correlation between for example the FEV1/FVC ratio and
the emphysema score is low: 8 out of 36 subjects with
emphysema on CT had a FEV1/FVC ratio above 70%.
In conclusion, spirometry is very important for the
diagnosis of emphysema, but it only measures airway
obstruction. The KNO is a very sensitive measure for the
detection of CT-based emphysema. The DLNO/DLCO ratio
is increased in (ex)smokers, which could be explained by
the hypothesis that pulmonary endothelial dysfunction
precedes extensive parenchymal loss ultimately leading
to airway obstruction. Further studies are needed to
explore this concept, in which the DLNO/DLCO ratio
could be used as a sensitive tool to detect microvascular
malfunctioning.
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